Verbalis Joseph G, Goldsmith Stephen R, Greenberg Arthur, Schrier Robert W, Sterns Richard H
Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University Medical Center, Washington, District of Columbia 20007, USA.
Am J Med. 2007 Nov;120(11 Suppl 1):S1-21. doi: 10.1016/j.amjmed.2007.09.001.
Although hyponatremia is a common, usually mild, and relatively asymptomatic disorder of electrolytes, acute severe hyponatremia can cause substantial morbidity and mortality, particularly in patients with concomitant disease. In addition, overly rapid correction of chronic hyponatremia can cause severe neurologic deficits and death, and optimal treatment strategies for such cases are not established. An expert panel assessed the potential contributions of aquaretic nonpeptide small-molecule arginine vasopressin receptor (AVPR) antagonists to hyponatremia therapies. This review presents their conclusions, including identification of appropriate treatment populations and possible future indications for aquaretic AVPR antagonists.
尽管低钠血症是一种常见的、通常较为轻微且相对无症状的电解质紊乱疾病,但急性重度低钠血症可导致严重的发病率和死亡率,尤其是在伴有其他疾病的患者中。此外,慢性低钠血症纠正过快可导致严重的神经功能缺损和死亡,而此类病例的最佳治疗策略尚未确立。一个专家小组评估了利水非肽小分子精氨酸血管加压素受体(AVPR)拮抗剂对低钠血症治疗的潜在作用。本综述介绍了他们的结论,包括确定合适的治疗人群以及利水AVPR拮抗剂未来可能的适应证。